Pozen (POZN): Another Microcap Biotech Falls Apart
Pozen (POZN) got the bad news that the FDA has "delayed approval of an experimental two-in-one migraine drug from GlaxoSmithKline (GSK)", according to Reuters. The drug, Trexima combines Glaxo’s popular migraine drug Imitrex with the older painkiller naproxen sodium. Pozen’s…
Pozen (POZN) got the bad news that the FDA has "delayed approval of an experimental two-in-one migraine drug from GlaxoSmithKline (GSK)", according to Reuters. The drug, Trexima combines Glaxo’s popular migraine drug Imitrex with the older painkiller naproxen sodium.
Pozen’s shares dropped 45% to $9.55. Its market cap is now $285 million, but over the last year, it has been as high as $500 million.
It is a frightening valuation for a company that is virtually a one-trick pony. In the last reported quarter, Pozen has revenue of $7.7 million and an operating loss of $2.9 million.
Even with the drop, the stock still seems high.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.





